Wedbush Expects Reduced Earnings for Intellia Therapeutics

Key Points

• Wedbush has lowered its Q3 2025 earnings per share estimate for Intellia Therapeutics from ($0.80) to ($0.96), maintaining a "Neutral" rating and a target price of $7.00.
• Intellia reported a quarterly loss of ($0.99) EPS, outperforming forecasts, with revenue increasing by 104.3% year-over-year to $14.25 million.
• Analysts are divided on the stock, with two sell ratings, six hold ratings, and twelve buy ratings, resulting in an average price target of $31.11.

Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) - Wedbush lowered their Q3 2025 earnings per share estimates for shares of Intellia Therapeutics in a research report issued on Thursday, August 7th. Wedbush analyst D. Nierengarten now forecasts that the company will post earnings per share of ($0.96) for the quarter, down from their previous estimate of ($0.80). Wedbush currently has a "Neutral" rating and a $7.00 target price on the stock. The consensus estimate for Intellia Therapeutics' current full-year earnings is ($5.07) per share. Wedbush also issued estimates for Intellia Therapeutics' Q4 2025 earnings at ($0.89) EPS, FY2025 earnings at ($3.94) EPS, Q1 2026 earnings at ($0.97) EPS, Q2 2026 earnings at ($1.04) EPS, Q3 2026 earnings at ($1.13) EPS, Q4 2026 earnings at ($1.22) EPS, FY2026 earnings at ($4.36) EPS, FY2027 earnings at ($3.02) EPS, FY2028 earnings at ($2.80) EPS and FY2029 earnings at ($2.59) EPS.

Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The company reported ($0.99) earnings per share for the quarter, topping the consensus estimate of ($1.03) by $0.04. Intellia Therapeutics had a negative return on equity of 54.90% and a negative net margin of 908.48%. The firm had revenue of $14.25 million during the quarter, compared to analyst estimates of $12.26 million. During the same period last year, the company posted ($1.52) EPS. The business's quarterly revenue was up 104.3% on a year-over-year basis.

A number of other analysts have also commented on the company. Chardan Capital reaffirmed a "buy" rating and issued a $68.00 target price on shares of Intellia Therapeutics in a research report on Friday, May 9th. Canaccord Genuity Group decreased their target price on Intellia Therapeutics from $74.00 to $54.00 and set a "buy" rating for the company in a research report on Tuesday, June 3rd. Wolfe Research raised Intellia Therapeutics from a "peer perform" rating to an "outperform" rating and set a $21.00 target price for the company in a research report on Monday, April 21st. Royal Bank Of Canada decreased their target price on Intellia Therapeutics from $25.00 to $21.00 and set an "outperform" rating for the company in a research report on Friday. Finally, Guggenheim decreased their target price on Intellia Therapeutics from $55.00 to $45.00 and set a "buy" rating for the company in a research report on Monday, May 12th. Two analysts have rated the stock with a sell rating, six have assigned a hold rating and twelve have given a buy rating to the company. According to MarketBeat, Intellia Therapeutics currently has an average rating of "Moderate Buy" and an average price target of $31.11.

Intellia Therapeutics Trading Down 5.8%

NTLA stock opened at $10.79 on Monday. The stock has a 50-day moving average price of $10.55 and a 200-day moving average price of $9.49. Intellia Therapeutics has a 1-year low of $5.90 and a 1-year high of $24.16. The firm has a market cap of $1.12 billion, a PE ratio of -2.30 and a beta of 2.31.

Hedge Funds Weigh In On Intellia Therapeutics

Institutional investors have recently modified their holdings of the business. GF Fund Management CO. LTD. bought a new position in shares of Intellia Therapeutics in the fourth quarter valued at approximately $25,000. Whipplewood Advisors LLC grew its holdings in shares of Intellia Therapeutics by 114,900.0% in the second quarter. Whipplewood Advisors LLC now owns 3,450 shares of the company's stock valued at $32,000 after acquiring an additional 3,447 shares in the last quarter. Northwestern Mutual Wealth Management Co. grew its holdings in shares of Intellia Therapeutics by 56.4% in the first quarter. Northwestern Mutual Wealth Management Co. now owns 4,590 shares of the company's stock valued at $33,000 after acquiring an additional 1,655 shares in the last quarter. Sterling Capital Management LLC grew its holdings in shares of Intellia Therapeutics by 866.2% in the fourth quarter. Sterling Capital Management LLC now owns 3,198 shares of the company's stock valued at $37,000 after acquiring an additional 2,867 shares in the last quarter. Finally, Harbour Investments Inc. grew its holdings in shares of Intellia Therapeutics by 76.7% in the first quarter. Harbour Investments Inc. now owns 5,214 shares of the company's stock valued at $37,000 after acquiring an additional 2,264 shares in the last quarter. 88.77% of the stock is owned by institutional investors.

Insider Buying and Selling

In other Intellia Therapeutics news, EVP Edward J. Dulac III sold 7,462 shares of the business's stock in a transaction that occurred on Wednesday, July 23rd. The stock was sold at an average price of $14.02, for a total transaction of $104,617.24. Following the completion of the sale, the executive vice president directly owned 106,062 shares of the company's stock, valued at approximately $1,486,989.24. The trade was a 6.57% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Over the last three months, insiders sold 12,534 shares of company stock worth $153,837. Insiders own 3.10% of the company's stock.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.